Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission has approved the use of UCB's Keppra in a new indication as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
Subscribe to our email newsletter
The new approval expands the indication for the drug, which is already approved for use in the treatment of partial onset epileptic seizures.
Juvenile myoclonic epilepsy (JME) is a common epilepsy syndrome that usually starts between the ages of 12 and 18 and accounts for about 10% of all cases of epilepsy. Myoclonic seizures are short, jerky muscle spasms that can occur once or repetitively, on one or both sides of the body.
“Keppra has over one million patient years' experience and continues to help many people with partial-onset seizures. This new indication supports Keppra's established efficacy and we are pleased that Keppra is now available to patients with myoclonic seizures in JME”, said Troy Cox, president CNS operations at UCB.